These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22334621)

  • 61. Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study.
    Newcorn JH; Stein MA; Cooper KM
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):187-96. PubMed ID: 20578931
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.
    Retz W; Rösler M; Ose C; Scherag A; Alm B; Philipsen A; Fischer R; Ammer R;
    World J Biol Psychiatry; 2012 Jan; 13(1):48-59. PubMed ID: 21155632
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The clinical profile of children with ADHD that require OROS-methylphenidate combined with shorter-acting formulations.
    Zelnik N; Terkel-Dawer R
    Atten Defic Hyperact Disord; 2015 Dec; 7(4):313-8. PubMed ID: 25838111
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial.
    Huss M; Ginsberg Y; Arngrim T; Philipsen A; Carter K; Chen CW; Gandhi P; Kumar V
    Clin Drug Investig; 2014 Sep; 34(9):639-49. PubMed ID: 25015027
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety.
    Golubchik P; Golubchik L; Sever JM; Weizman A
    Int Clin Psychopharmacol; 2014 Sep; 29(5):274-8. PubMed ID: 24743562
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An open-label trial of OROS methylphenidate in adults with late-onset ADHD.
    Biederman J; Mick E; Spencer T; Surman C; Hammerness P; Doyle R; Dougherty M; Aleardi M; Schweitzer K
    CNS Spectr; 2006 May; 11(5):390-6. PubMed ID: 16641844
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Addition of methylphenidate to intensive dialectical behaviour therapy for patients suffering from comorbid borderline personality disorder and ADHD: a naturalistic study.
    Prada P; Nicastro R; Zimmermann J; Hasler R; Aubry JM; Perroud N
    Atten Defic Hyperact Disord; 2015 Sep; 7(3):199-209. PubMed ID: 25634471
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of osmotic-release oral system methylphenidate on learning skills in adolescents with attention-deficit/hyperactivity disorder: an open-label study.
    Na KS; Lee SI; Hong SD; Kim JH; Shim SH; Choi J; Yang J; Lee MS; Joung YS; Kim EJ; Park JH
    Int Clin Psychopharmacol; 2013 Jul; 28(4):184-92. PubMed ID: 23587983
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD.
    Luo SX; Covey LS; Hu MC; Winhusen TM; Nunes EV
    Am J Addict; 2019 Nov; 28(6):497-502. PubMed ID: 31538372
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension.
    Ginsberg Y; Lindefors N
    Br J Psychiatry; 2012 Jan; 200(1):68-73. PubMed ID: 22075648
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder.
    Kim Y; Kim B; Chang JS; Kim BN; Cho SC; Hwang JW
    Psychiatry Clin Neurosci; 2014 Jul; 68(7):506-14. PubMed ID: 24417707
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Is response to OROS-methylphenidate treatment moderated by treatment with antidepressants or psychiatric comorbidity? A secondary analysis from a large randomized double blind study of adults with ADHD.
    Biederman J; Mick E; Spencer T; Surman C; Faraone SV
    CNS Neurosci Ther; 2012 Feb; 18(2):126-32. PubMed ID: 22070421
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder.
    Findling RL; Katic A; Rubin R; Moon E; Civil R; Li Y
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):365-75. PubMed ID: 20973707
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.
    Maia CR; Matte BC; Ludwig HT; Rohde LA
    Eur Child Adolesc Psychiatry; 2008 Apr; 17(3):133-42. PubMed ID: 17846812
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.
    Di Martino A; Melis G; Cianchetti C; Zuddas A
    J Child Adolesc Psychopharmacol; 2004; 14(2):207-18. PubMed ID: 15319018
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS).
    Vitiello B; Abikoff HB; Chuang SZ; Kollins SH; McCracken JT; Riddle MA; Swanson JM; Wigal T; McGough JJ; Ghuman JK; Wigal SB; Skrobala AM; Davies M; Posner K; Cunningham C; Greenhill LL
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):593-604. PubMed ID: 17979580
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review].
    Lv XZ; Shu Z; Zhang YW; Wu SS; Zhan SY
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 May; 13(5):365-9. PubMed ID: 21575338
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality-of-life outcomes.
    Döpfner M; Breuer D; Walter D; Rothenberger A
    Eur Child Adolesc Psychiatry; 2011 Oct; 20 Suppl 2(Suppl 2):S277-88. PubMed ID: 21901414
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Psychosis in a cocaine-dependent patient with ADHD during treatment with methylphenidate.
    Delavenne H; Duarte Garcia F; Lacoste J; Cortese S; Charles-Nicolas A; Ballon N
    Gen Hosp Psychiatry; 2013; 35(4):451.e7-9. PubMed ID: 22739113
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study.
    Kronenberger WG; Giauque AL; Lafata DE; Bohnstedt BN; Maxey LE; Dunn DW
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):334-47. PubMed ID: 17630867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.